Clinical trials: Indolent Lymphoma
Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to evaluate the 28-day safety and tolerability, and to determine the pharmacokinetics (PK) of idelalisib in Japanese participants with relapsed or refractory indolent B-cell non-Hodgkin…
- Conditions
- Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT02242045
- Testing
- Idelalisib
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Gilead Sciences
Indolent Lymphoproliferative Disorders
Low Grade Lymphoma
The purpose of this study is to assess the seroconversion rate and the cellular immune response after vaccination against hepatitis B virus in patients with lymphoproliferative syndrome like chronic lymphocytic leukemia stade A…
- Trial name
- EVACC-B (NCT01698866)
- Testing
- Vaccin GenHevac B Pasteur
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Central Hospital, Nancy, France
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.
- Trial name
- NCT02384954
- Testing
- Rituximab, N-803
- Where
- 4 sites in United States
- Volunteers
- 43 people
- Sponsor
- Altor BioScience
Non-Hodgkins Lymphoma
Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma
The purpose of this study is to investigate the ability to combine a radioactive medication directly targeted against lymphoma cells with the immune effects of an allogeneic blood stem cell transplant.
- Trial name
- NCT00807196
- Testing
- Rituximab, 90Y ibritumomab tiuxetan (Zevalin), Cyclophosphamide
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Phase II trial to study the effectiveness of 506U78 in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or T-cell lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma
- Trial name
- NCT00005950
- Testing
- nelarabine
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin Lymphoma
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
The purpose of this study is to determine the rate of response to the drugs bortezomib (Velcade) and vorinostat (Zolinza), when used in combination, in patients with relapsed (recurrent) and/or refractory (difficult to treat)…
- Trial name
- COMBOSTAT (NCT00837174)
- Testing
- Vorinostat in combination with Bortezomib
- Sponsor
- The Methodist Hospital Research Institute
Follicular Lymphomas, Immunocytomas
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no…
- Conditions
- Follicular Lymphomas, Immunocytomas, Marginal Zone Lymphomas, Mantle-Cell Lymphomas
- Trial name
- MAINTAIN (NCT00877214)
- Testing
- Rituximab, Rituximab / observation
- Where
- Germany
- Volunteers
- 1,272 people
- Sponsor
- Jurgen Barth
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma
An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma
- Trial name
- NCT04447716
- Testing
- Venetoclax, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Indolent Lymphomas, Lymphoma
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas.
- Conditions
- Indolent Lymphomas, Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06860880
- Testing
- Exercise, Diet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Lymphoma, B-Cell
Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma
A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.
- Trial name
- RIPPLE (NCT04246359)
- Testing
- Rituximab Biosimilar, Pegylated Interferon α-2b
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Huiqiang Huang
B-cell Lymphoma, Non Hodgkin Lymphoma
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.
- Conditions
- B-cell Lymphoma, Non Hodgkin Lymphoma, Multiple Myeloma, Follicular Lymphoma
- Trial name
- NCT03424603
- Testing
- STRO-001
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- Sutro Biopharma, Inc.
Soft Tissue Sarcomas, Thyroid Cancer
11C-Acetate PET/CT Non-FDG-Avid Tumors
F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor.
- Conditions
- Soft Tissue Sarcomas, Thyroid Cancer, Lung Cancer, Indolent Lymphoma
- Trial name
- NCT00687778
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Indolent B-cell Lymphoma, Hepatitis C
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell…
- Trial name
- NCT02836925
- Testing
- Ledipasvir+Sofosbuvir, Sofosbuvir+Velpatasvir
- Where
- 13 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004198
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- United States
- Sponsor
- University of Nebraska
Follicular Lymphoma, Marginal Zone Lymphoma
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Ofatumumab is a drug that works by attaching to the CD20 molecule found on the surface of cancerous B cells, and then triggering the death of those cells.
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT01239394
- Testing
- ofatumumab
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Massachusetts General Hospital
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
This phase II trial studies how well giving vorinostat, cladribine, and rituximab together works in treating patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or B cell non-Hodgkin's lymphoma (NHL)…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT00764517
- Testing
- Cladribine, Laboratory Biomarker Analysis, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- OHSU Knight Cancer Institute
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic…
- Trial name
- NCT05876923
- Testing
- Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry
- Where
- 2 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Lymphoma, Non-Hodgkin
Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.
Pilot multicentre, open label study with the aim to evaluate antitumor activity in term of the sum of complete and partial response (O.R.R.) of chemotherapy (cyclophosphamide and fludarabine) and rituximab, followed by zevalin…
- Trial name
- Z0105 (NCT00354822)
- Testing
- Zevalin
- Where
- 6 sites in Italy
- Volunteers
- 25 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Indolent B-Cell Lymphomas
Indolent Non Follicular Lymphomas Prognostic Project
Prospective collection of data of possible prognostic relevance in patients with indolent non - follicular B-CELL Lymphomas.
- Trial name
- NCT02904577
- Testing
- Any treatment, watch and wait policy included
- Where
- 46 sites in Austria, Brazil and 4 more
- Volunteers
- 370 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Non-Hodgkin's Lymphoma (NHL)
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent…
- Trial name
- NCT01108341
- Testing
- Bendamustine hydrochloride, Ofatumumab
- Where
- 39 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Cephalon